Tactive Advisors’s Biogen BIIB Stock Holding History

Tactive Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,389	Closed	-$1.22M	–	55
2022 Q4	$1.22M	Buy	+4,389	New	+$1.24M	0.79%	23

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Tactive Advisors's BIIB Position: Q1 2023 in Review

Tactive Advisors sold out of Biogen (BIIB) in Q1 2023, closing a stake of 4,389 shares — an estimated $1.22M sold.

Tactive Advisors first reported a position in BIIB in Q4 2022 and held it in 1 quarter. The position peaked at $1.22M in Q4 2022. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q1 2023.

Tactive Advisors reported no remaining Biogen position as of Q1 2023 after selling out during the quarter.
Tactive Advisors sold 4,389 Biogen shares in Q1 2023, an estimated $1.22M.
Tactive Advisors first reported a position in Biogen in Q4 2022 and held it in 1 quarter.
Tactive Advisors's Biogen position peaked at $1.22M in Q4 2022.
1,001 funds tracked by Wall St. Rank held Biogen as of Q1 2023.

Based on Tactive Advisors's 13F filing for Q1 2023, filed 2 Feb 2024.